at Sarepta to get a preview of what will happen on good news coming out of the HIV trial. You either believe it will work or it won't....the results, whichever way they fall, should not be unambiguous...GLTA
Well, yes and no. The most recent results in HIV showed that five of nine subjects had T-cell levels rise to a level that would be deemed acceptable to remain off of HAART. Those are good numbers indeed. However, considering the four patients who didn't make it to that level, the results are not entirely unambiguous. It may be that other factors—including related illness and/or each person's unique biological pathway—kept T-cell levels from being higher in the remaining four subjects. They, too, may have risen but not quite to the level needed to remain off of HAART.
Based on the data thus far, I expect the results to be positive—I absolutely hope they are—but not without the complexities that are inherent to biology and science.
This was a dose escalation (safety) study! All patients were not even receiving a therapeutic dose! Given that, the fact that more than half of the patients had nevertheless risen to a level above that generally considered good enough to go off of HAART is hugely positive. Note also that this is an earlier version of the drug and there are improved versions already in the clinical trials process: the Cyclophosphamide to increase the number of cells, etc.